<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ESC Heart Fail</journal-id><journal-id journal-id-type="iso-abbrev">ESC Heart Fail</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2055-5822</journal-id><journal-id journal-id-type="publisher-id">EHF2</journal-id><journal-title-group><journal-title>ESC Heart Failure</journal-title></journal-title-group><issn pub-type="epub">2055-5822</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29469177</article-id><article-id pub-id-type="pmc">5933961</article-id><article-id pub-id-type="doi">10.1002/ehf2.12272</article-id><article-id pub-id-type="publisher-id">EHF212272</article-id><article-id pub-id-type="other">ESCHF-17-00090</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research Articles</subject></subj-group></article-categories><title-group><article-title>Haemodynamic effects of levosimendan in advanced but stable chronic heart failure</article-title><alt-title alt-title-type="right-running-head">Levosimendan in stable heart failure</alt-title><alt-title alt-title-type="left-running-head">E. Najjar <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="ehf212272-cr-0001" contrib-type="author" corresp="yes"><name><surname>Najjar</surname><given-names>Emil</given-names></name><address><email>emil.najjar@karolinska.se</email></address><xref ref-type="aff" rid="ehf212272-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ehf212272-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ehf212272-cr-0002" contrib-type="author"><name><surname>St&#x000e5;lhberg</surname><given-names>Marcus</given-names></name><xref ref-type="aff" rid="ehf212272-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ehf212272-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ehf212272-cr-0003" contrib-type="author"><name><surname>Hage</surname><given-names>Camilla</given-names></name><xref ref-type="aff" rid="ehf212272-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ehf212272-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ehf212272-cr-0004" contrib-type="author"><name><surname>Ottenblad</surname><given-names>Erica</given-names></name><xref ref-type="aff" rid="ehf212272-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ehf212272-cr-0005" contrib-type="author"><name><surname>Manouras</surname><given-names>Aristomenis</given-names></name><xref ref-type="aff" rid="ehf212272-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ehf212272-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ehf212272-cr-0006" contrib-type="author"><name><surname>Haugen L&#x000f6;fman</surname><given-names>Ida</given-names></name><xref ref-type="aff" rid="ehf212272-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ehf212272-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ehf212272-cr-0007" contrib-type="author"><name><surname>Lund</surname><given-names>Lars H.</given-names></name><xref ref-type="aff" rid="ehf212272-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ehf212272-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="ehf212272-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Karolinska Institutet</institution>
<named-content content-type="post-code">17177</named-content>
<named-content content-type="city">Stockholm</named-content>
<country country="SE">Sweden</country>
</aff><aff id="ehf212272-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Karolinska University Hospital</institution>
<named-content content-type="post-code">17176</named-content>
<named-content content-type="city">Stockholm</named-content>
<country country="SE">Sweden</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence to: Emil Najjar, MD, Department of Medicine, Unit of Cardiology, Karolinska Institutet, Karolinska University Hospital, N305 17176 Stockholm, Sweden. Tel: +46 739901661.<break/>
Email: <email>emil.najjar@karolinska.se</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2018</year></pub-date><volume>5</volume><issue>3</issue><issue-id pub-id-type="doi">10.1002/ehf2.v5.3</issue-id><fpage>302</fpage><lpage>308</lpage><history><date date-type="received"><day>07</day><month>6</month><year>2017</year></date><date date-type="rev-recd"><day>06</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>09</day><month>1</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 The Heart Failure Association of the European Society of Cardiology / John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. ESC Heart Failure published by John Wiley &#x00026; Sons Ltd on behalf of the European Society of Cardiology.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EHF2-5-302.pdf"/><abstract><title>Abstract</title><sec id="ehf212272-sec-0001"><title>Aims</title><p>Levosimendan improves haemodynamics in acute decompensated heart failure (HF). However, it is increasingly used for repetitive or intermittent infusions in advanced but stable chronic HF, without clear indication, selection criteria, or effect. We tested the hypotheses that (1) levosimendan improves haemodynamics in stable chronic HF and (2) that the response is dependent on baseline clinical and haemodynamic factors.</p></sec><sec id="ehf212272-sec-0002"><title>Methods and results</title><p>Twenty&#x02010;three patients [median age 56 (49&#x02013;64)&#x000a0;years, four (17%) women] with stable New York Heart Association (NYHA) III and IV HF received a single 24&#x000a0;h levosimendan infusion. Non&#x02010;invasive haemodynamics (inert gas re&#x02010;breathing technique), estimated glomerular filtration rate, and N&#x02010;terminal pro&#x02010;brain natriuretic peptide were assessed before and after infusion. Levosimendan had the following effects (median change): a significant increase in cardiac output (+9.8&#x000a0;&#x000b1;&#x000a0;21.6%; <styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.026) and decrease in N&#x02010;terminal pro&#x02010;brain natriuretic peptide (&#x02212;28.1&#x000a0;&#x000b1;&#x000a0;16.3%, <styled-content style="italic-in-any-context">P</styled-content>&#x000a0;&#x0003c;&#x000a0;0.001), estimated total peripheral resistance (&#x02212;16.9&#x000a0;&#x000b1;&#x000a0;18.3%, <styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.005), and mean arterial pressure (&#x02212;5.9&#x000a0;&#x000b1;&#x000a0;8.2%, <styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.007), but no change in estimated glomerular filtration rate (+0.89&#x000a0;&#x000b1;&#x000a0;14.0%, <styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.955). There were no significant associations between baseline clinical and/or haemodynamic factors and the levosimendan effect on cardiac output.</p></sec><sec id="ehf212272-sec-0003"><title>Conclusions</title><p>Levosimendan was associated with improved haemodynamics in patients with stable chronic HF, but we could not identify any predictors of the magnitude of haemodynamic response.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ehf212272-kwd-0001">Heart failure</kwd><kwd id="ehf212272-kwd-0002">Repetitive treatment</kwd><kwd id="ehf212272-kwd-0003">Inotrope</kwd><kwd id="ehf212272-kwd-0004">Inodilator</kwd><kwd id="ehf212272-kwd-0005">Levosimendan</kwd><kwd id="ehf212272-kwd-0006">Cardiac output</kwd></kwd-group><funding-group><award-group><funding-source>OrionPharma Inc</funding-source></award-group><award-group><funding-source>Stockholm County Council</funding-source><award-id>20090556</award-id><award-id>20110120</award-id></award-group><award-group><funding-source>Swedish Heart Lung Foundation</funding-source><award-id>20150063</award-id></award-group><award-group><funding-source>Swedish Research Council</funding-source><award-id>2013&#x02010;23897&#x02010;104604&#x02010;23</award-id></award-group><award-group><funding-source>OrionPharma Inc.</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="7"/><word-count count="2550"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>ehf212272</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.7.2 mode:remove_FC converted:03.05.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ehf212272-cit-0000">
<string-name>
<surname>Najjar</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>St&#x000e5;lhberg</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hage</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Ottenblad</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Manouras</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Haugen L&#x000f6;fman</surname>, <given-names>I.</given-names>
</string-name>, and <string-name>
<surname>Lund</surname>, <given-names>L. H.</given-names>
</string-name> (<year>2018</year>) <article-title>Haemodynamic effects of levosimendan in advanced but stable chronic heart failure</article-title>. <source>ESC Heart Failure</source>, <volume>5</volume>: <fpage>302</fpage>&#x02013;<lpage>308</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1002/ehf2.12272">10.1002/ehf2.12272</ext-link>.</mixed-citation>
</p></notes></front><body><sec id="ehf212272-sec-0004"><title>Introduction</title><p>Heart failure (HF) has a prevalence and incidence rates of 2&#x02013;3% and 0.5%, respectively, and is associated with severely compromised quality of life, poor prognosis, and high costs to society.<xref rid="ehf212272-bib-0001" ref-type="ref">1</xref>, <xref rid="ehf212272-bib-0002" ref-type="ref">2</xref> Acute decompensated HF (ADHF) is the most common cause of hospitalization,<xref rid="ehf212272-bib-0003" ref-type="ref">3</xref> and cardiogenic shock occurs in about 4% of ADHF admissions.<xref rid="ehf212272-bib-0004" ref-type="ref">4</xref> Conventional inotropes improve haemodynamics and organ perfusion and relieve symptoms, but due to short half&#x02010;lives, they are limited to selected inpatients and outpatients with continuous infusions and are pro&#x02010;ischaemic, are pro&#x02010;arrhythmic, and may be associated with increased mortality.<xref rid="ehf212272-bib-0005" ref-type="ref">5</xref>, <xref rid="ehf212272-bib-0006" ref-type="ref">6</xref>, <xref rid="ehf212272-bib-0007" ref-type="ref">7</xref>, <xref rid="ehf212272-bib-0008" ref-type="ref">8</xref>, <xref rid="ehf212272-bib-0009" ref-type="ref">9</xref>
</p><p>Levosimendan is an intravenous inodilator agent whose inotropic effect is mediated primarily by calcium sensitization, without concomitant increase in intracellular calcium levels or myocardial metabolic demand.<xref rid="ehf212272-bib-0010" ref-type="ref">10</xref>, <xref rid="ehf212272-bib-0011" ref-type="ref">11</xref> In early studies in ADHF, levosimendan improved haemodynamics and mortality compared with dobutamine<xref rid="ehf212272-bib-0012" ref-type="ref">12</xref> and placebo.<xref rid="ehf212272-bib-0013" ref-type="ref">13</xref> In later studies, it was not superior to dobutamine,<xref rid="ehf212272-bib-0014" ref-type="ref">14</xref> and it improved symptoms but increased hypotension and arrhythmia compared with placebo.<xref rid="ehf212272-bib-0015" ref-type="ref">15</xref>
</p><p>Advanced but stable chronic HF affects up to 5% of the HF population and is characterized by a low&#x02010;output state, severe symptoms, frequent hospitalizations, and high mortality.<xref rid="ehf212272-bib-0005" ref-type="ref">5</xref>, <xref rid="ehf212272-bib-0016" ref-type="ref">16</xref> Continuous outpatient conventional inotrope infusions may be required to keep patients out of hospital and to preserve perfusion and end organ function, for example, in patients awaiting heart transplantation, especially those who may not be suitable for bridging with left ventricular assist device (LVAD). However, this practice is still controversial and may be associated with increased mortality.<xref rid="ehf212272-bib-0017" ref-type="ref">17</xref>, <xref rid="ehf212272-bib-0018" ref-type="ref">18</xref>, <xref rid="ehf212272-bib-0019" ref-type="ref">19</xref>
</p><p>Levosimendan has an active metabolite that peaks 80&#x02013;90&#x000a0;h after administration, and the beneficial haemodynamic effects are sustained for at least 7&#x000a0;days.<xref rid="ehf212272-bib-0020" ref-type="ref">20</xref> This has led to a growing but highly variable practice of intermittent (as needed) or repetitive (planned) treatment in advanced but stable HF.<xref rid="ehf212272-bib-0021" ref-type="ref">21</xref> This may be beneficial in select patients.<xref rid="ehf212272-bib-0019" ref-type="ref">19</xref>, <xref rid="ehf212272-bib-0022" ref-type="ref">22</xref> The LevoRep trial did show improved 6&#x000a0;min walking capacity and improved Kansas City Cardiomyopathy Questionnaire but did not meet the high primary endpoint criteria; however, effects on secondary endpoints were promising.<xref rid="ehf212272-bib-0023" ref-type="ref">23</xref> The LION&#x02010;HEART trial showed lower N&#x02010;terminal pro&#x02010;brain natriuretic peptide (NT&#x02010;pro&#x02010;BNP) area under the curve and the secondary endpoints HF hospitalization and combined HF hospitalization and death.<xref rid="ehf212272-bib-0024" ref-type="ref">24</xref> However, confirmatory trials are needed, and in particular, improved selection of patients most likely to respond and derive benefit is needed. Therefore, we tested the hypotheses that (1) levosimendan improves haemodynamics also in stable chronic HF and (2) that the response is dependent on baseline clinical and/or haemodynamic factors.</p></sec><sec id="ehf212272-sec-0005"><title>Methods</title><sec id="ehf212272-sec-0006"><title>Study population</title><p>This was a prospective single&#x02010;centre single&#x02010;arm trial of adult patients with advanced but stable chronic HF with New York Heart Association class (NYHA) III and IV symptoms and an ejection fraction (EF) of &#x0003c;40%, who were scheduled for elective intravenous levosimendan infusion based on consensus clinical indication at the Karolinska University Hospital. Patients were either listed for or undergoing evaluation for heart transplantation, LVAD, or palliative care. Patients were excluded if they were unable or unwilling to participate in the study protocol.</p><p>The study protocol conformed to the Declaration of Helsinki and received approval from the regional ethical review board. Written informed consent has been obtained from all patients.</p></sec><sec id="ehf212272-sec-0007"><title>Intervention: levosimendan infusion</title><p>All patients reported to the hospital ward in the morning and received a single 24&#x000a0;h levosimendan infusion initially at a rate of 0.1&#x000a0;&#x003bc;g/kg/min without bolus. If the patient tolerated the initial dosage and based on clinical judgment, we gradually increased the infusion rate to 0.2&#x000a0;&#x003bc;g/kg/min. The infusions were maintained at a constant rate for 24&#x000a0;h, unless symptomatic hypotension, defined as systolic blood pressure below 80&#x000a0;mmHg, occurred or the patient had a major cardiovascular event like arrhythmia. In case of hypotension or a major cardiovascular event, the infusion was stopped for 30&#x02013;60&#x000a0;min or until the dose&#x02010;limiting event had resolved and then restarted at half the rate being received at the time of the untoward reaction.</p></sec><sec id="ehf212272-sec-0008"><title>Data collection and analysis</title><p>Prior to and immediately after the 24&#x000a0;h infusion, physical examination and non&#x02010;invasive haemodynamic evaluation were performed using an inert gas re&#x02010;breathing method (Innocor&#x000ae; Innovision A/S, Denmark), and plasma samples for creatinine and NT&#x02010;pro&#x02010;BNP were collected. The Innocor is an established, safe, and non&#x02010;invasive technique for assessing pulmonary blood flow (PBF) and cardiac output (CO). It uses a gas mixture that contains two inert compounds in a closed re&#x02010;breathing system; one compound is blood soluble (N<sub>2</sub>O), whereas the other is insoluble (SF<sub>6</sub>). The soluble gas dissolves in the blood of the pulmonary capillaries and is subsequently washed out by the blood perfusing the lungs. Therefore, the disappearance rate of N<sub>2</sub>O from expired air is directly proportional to the PBF, which in turn equals CO in the absence of significant shunting. Thus, we report PBF, but for purposes of discussion, refer to changes in CO. This technique has been validated against invasive measurements of CO in HF patients (direct Fick, thermodilution, and dye dilution) and is safe and accurate in different clinical settings.<xref rid="ehf212272-bib-0025" ref-type="ref">25</xref>, <xref rid="ehf212272-bib-0026" ref-type="ref">26</xref>, <xref rid="ehf212272-bib-0027" ref-type="ref">27</xref>
</p><p>Estimated total peripheral resistance (eTPR) was calculated using the formula eTPR&#x000a0;=&#x000a0;[mean arterial pressure (MAP)&#x000a0;&#x02212;&#x000a0;central venous pressure]/CO&#x000a0;&#x000d7;&#x000a0;80 and was simplified by assuming that central venous pressure was 15. The estimated glomerular filtration rate was determined using the chronic kidney disease epidemiology collaboration formula.<xref rid="ehf212272-bib-0026" ref-type="ref">26</xref>
</p></sec><sec id="ehf212272-sec-0009"><title>Statistical analysis</title><p>Statistical analysis was performed using SPSS Version 22.0 (SPSS Inc., Chicago, IL, USA). All continuous variables were tested for normal distribution using the Kolmogorov&#x02013;Smirnov test and expressed as median (interquartile range), while categorical variables were expressed as <italic>n</italic> and percentages. Significant testing between continuous variables was subsequently performed using the Mann&#x02013;Whitney U test (skewed variables). Similarly, Wilcoxon's paired test (skewed data) was used to compare median values before and after each infusion. Association between baseline clinical and haemodynamic factors and the outcome change in CO was analysed using Spearman's correlations. A two&#x02010;sided <italic>P</italic> value of &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec id="ehf212272-sec-0010"><title>Results</title><p>We included 23 patients [median age 56 (49&#x02013;64) years, four women (17%)] with median EF 20% (15&#x02013;31%) and NYHA IIIA (<italic>n</italic>&#x000a0;=&#x000a0;4, 17.4%), NYHA IIIB (<italic>n</italic>&#x000a0;=&#x000a0;18, 78.3%), or NYHA IV (<italic>n</italic>&#x000a0;=&#x000a0;1, 4.4%). <italic>Table</italic>
<xref rid="ehf212272-tbl-0001" ref-type="table-wrap">1</xref> details the baseline characteristics. Median CO was 3.05&#x000a0;L/min (2.8&#x02013;3.4), median NT&#x02010;pro&#x02010;BNP 3400&#x000a0;pg/mL (1882&#x02013;6597), median MAP 79&#x000a0;mmHg (74&#x02013;87), and median eTPR 1628&#x000a0;<ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Dyne">https://en.wikipedia.org/wiki/Dyne</ext-link>&#x000b7;s/cm<sup>5</sup> (1405&#x02013;2034). The target levosimendan dose was reached in all patients.</p><table-wrap id="ehf212272-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Variable</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Demographics</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">56 (49&#x02013;64)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female gender (<italic>n</italic>/%)</td><td align="left" valign="top" rowspan="1" colspan="1">4/17</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Haemodynamics and heart failure characteristics</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Heart rate (b.p.m.)</td><td align="left" valign="top" rowspan="1" colspan="1">69 (61&#x02013;73)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" valign="top" rowspan="1" colspan="1">101 (98&#x02013;105)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" valign="top" rowspan="1" colspan="1">68 (63&#x02013;73)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mean blood pressure (mmHg)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (74&#x02013;87)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cardiac output (L/min)</td><td align="left" valign="top" rowspan="1" colspan="1">3.1 (2.8&#x02013;3.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">NT&#x02010;pro&#x02010;BNP (pg/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">3400 (1882&#x02013;6597)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">eGFR (mL/min/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">62 (35&#x02013;78)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">eTPR (<ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Dyne">https://en.wikipedia.org/wiki/Dyne</ext-link>&#x000b7;s/cm<sup>5</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">1628 (1405&#x02013;2034)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BSA (m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">2.0 (1.9&#x02013;2.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">EF (%)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (15&#x02013;31)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">NYHA class: IIIA/IIIB/IV (<italic>n</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">4/18/1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sinus rhythm (<italic>n</italic>/%)</td><td align="left" valign="top" rowspan="1" colspan="1">8/35</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Atrial fibrillation</td><td align="left" valign="top" rowspan="1" colspan="1">15/65</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Device therapy</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PM (<italic>n</italic>/%)</td><td align="left" valign="top" rowspan="1" colspan="1">1/4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ICD (<italic>n</italic>/%)</td><td align="left" valign="top" rowspan="1" colspan="1">6/21</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CRT&#x02010;P (<italic>n</italic>/%)</td><td align="left" valign="top" rowspan="1" colspan="1">1/4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CRT&#x02010;D (<italic>n</italic>/%)</td><td align="left" valign="top" rowspan="1" colspan="1">15/65</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Medical therapy</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Beta&#x02010;blockers (<italic>n</italic>/%)</td><td align="left" valign="top" rowspan="1" colspan="1">22/95</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ACEI/ARB (<italic>n</italic>/%)</td><td align="left" valign="top" rowspan="1" colspan="1">22/95</td></tr></tbody></table><table-wrap-foot><fn id="ehf212272-note-0001"><p>ACEI, angiotensin&#x02010;converting enzyme inhibitor; ARB, angiotensin receptor blocker; BSA, body surface area; CRT, cardiac resynchronization therapy; EF, ejection fraction; eGFR, estimated glomerular filtration rate; eTPR, estimated total peripheral resistance; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association functional classification; NT&#x02010;pro&#x02010;BNP, N&#x02010;terminal pro&#x02010;brain natriuretic peptide; PM, pacemaker. Continuous variables are presented as median and interquartile range (Q1&#x02013;Q3) and categorical variables as numbers (<italic>n</italic>) and percentages.</p></fn></table-wrap-foot></table-wrap><p>
<italic>Figure</italic>
<xref rid="ehf212272-fig-0001" ref-type="fig">
<italic>1</italic>
</xref> illustrates the effect of levosimendan on CO. Levosimendan infusion was associated with a significant increase in CO from 3.05&#x000a0;L/min (2.8&#x02013;3.4) to 3.45&#x000a0;L/min (3.1&#x02013;4.2), corresponding to a median change of +9.8&#x000a0;&#x000b1;&#x000a0;21.6%, <italic>P</italic>&#x000a0;=&#x000a0;0.026.</p><fig fig-type="Figure" xml:lang="en" id="ehf212272-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Individual and median (interquartile range) cardiac output before and after levosimendan infusion.</p></caption><graphic id="nlm-graphic-1" xlink:href="EHF2-5-302-g001"/></fig><p>
<italic>Figure</italic>
<xref rid="ehf212272-fig-0002" ref-type="fig">
<italic>2</italic>
</xref> shows the effect of a single 24&#x000a0;h levosimendan infusion on the remaining study variables. Levosimendan infusion caused a significant decrease in NT&#x02010;pro&#x02010;BNP from 3400&#x000a0;pg/mL (1882&#x02013;6597) to 2530&#x000a0;pg/mL (1108&#x02013;6410), corresponding to a median change of &#x02212;28.1&#x000a0;&#x000b1;&#x000a0;16.3%, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001; eTPR from 1628 <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Dyne">https://en.wikipedia.org/wiki/Dyne</ext-link>&#x000b7;s/cm<sup>5</sup> (1405&#x02013;2034) to 1343&#x000a0;dyn&#x000b7;s/cm<sup>5</sup> (1151&#x02013;1701), corresponding to a median change of &#x02212;18.2&#x000a0;&#x000b1;&#x000a0;18.6%, <italic>P</italic>&#x000a0;=&#x000a0;0.004; and MAP from 79&#x000a0;mmHg (74&#x02013;87) to 74&#x000a0;mmHg (69&#x02013;81) corresponding to a median change of 5.9&#x000a0;&#x000b1;&#x000a0;8.2%, <italic>P</italic>&#x000a0;=&#x000a0;0.007. The estimated glomerular filtration rate showed insignificant change from 62&#x000a0;mL/min/m<sup>2</sup> (35&#x02013;78) to 61&#x000a0;mL/min/m<sup>2</sup> (40&#x02013;85), corresponding to a median change 0.89&#x000a0;&#x000b1;&#x000a0;14.0%, <italic>P</italic>&#x000a0;=&#x000a0;0.955.</p><fig fig-type="Figure" xml:lang="en" id="ehf212272-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Effect of a single 24&#x000a0;h levosimendan infusion on N&#x02010;terminal pro&#x02010;brain natriuretic peptide (NT&#x02010;pro&#x02010;BNP), estimated glomerular filtration rate (eGFR), mean arterial pressure (MAP), and estimated total peripheral resistance (eTPR). Error Bars represent median change and standard deviation.</p></caption><graphic id="nlm-graphic-3" xlink:href="EHF2-5-302-g002"/></fig><p>The levosimendan&#x02010;associated increase in CO was due to an increased stroke volume from 48&#x000a0;mL/min (40&#x02013;53) to 52&#x000a0;mL/min (46&#x02013;61), corresponding to a median change of 7.5&#x000a0;&#x000b1;&#x000a0;22.6%, <italic>P</italic>&#x000a0;=&#x000a0;0.021, since heart rate was unchanged from 69&#x000a0;b.p.m. (62&#x02013;74) to 70&#x000a0;b.p.m. (61&#x02013;76), corresponding to a median change of 0.67&#x000a0;&#x000b1;&#x000a0;6.5%, <italic>P</italic>&#x000a0;=&#x000a0;0.159.</p><p>In correlations analyses, <italic>Figure</italic>
<xref rid="ehf212272-fig-0003" ref-type="fig">
<italic>3</italic>
</xref>
<italic>A&#x02013;F</italic> illustrates the correlation between baseline clinical/haemodynamic factors and the change in CO. We found no significant correlation between baseline characteristics or haemodynamic variables and the change in CO.</p><fig fig-type="Figure" xml:lang="en" id="ehf212272-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Correlations between baseline cardiac output (CO) (A), N&#x02010;terminal pro&#x02010;brain natriuretic peptide (NT&#x02010;pro&#x02010;BNP) (B), estimated glomerular filtration rate (eGFR) (C), mean arterial pressure (MAP) (D), estimated total peripheral resistance (eTPR) (E), and age (F) and change in cardiac output in response to levosimendan.</p></caption><graphic id="nlm-graphic-5" xlink:href="EHF2-5-302-g003"/></fig></sec><sec id="ehf212272-sec-0011"><title>Discussion</title><p>To our knowledge, this is the first study to show that levosimendan improves CO also in advanced but stable chronic HF. There are no previous data about the levosimendan effect in patients with advanced but stable chronic HF; however, two previous studies have shown improvement in haemodynamic function measured by invasive haemodynamic monitoring in patients with decompensated HF.<xref rid="ehf212272-bib-0012" ref-type="ref">12</xref>, <xref rid="ehf212272-bib-0028" ref-type="ref">28</xref> Moreover, we confirmed findings from previous studies documenting that levosimendan also reduces NT&#x02010;pro&#x02010;BNP, MAP, and eTPR.<xref rid="ehf212272-bib-0029" ref-type="ref">29</xref>, <xref rid="ehf212272-bib-0030" ref-type="ref">30</xref>, <xref rid="ehf212272-bib-0031" ref-type="ref">31</xref> However, given that levosimendan is frequently used in stable HF despite a lack of convincing evidence or indications, we also examined whether baseline clinical and haemodynamic factors affected the response to levosimendan and observed no significant association between baseline clinical or haemodynamic parameters and levosimendan effect on CO.</p><p>Levosimendan was first approved in Sweden in the year 2000 and subsequently throughout Europe, and the early LIDO<xref rid="ehf212272-bib-0012" ref-type="ref">12</xref> and RUSSLAN<xref rid="ehf212272-bib-0013" ref-type="ref">13</xref> trials were promising. However, the larger SURVIVE<xref rid="ehf212272-bib-0014" ref-type="ref">14</xref> and REVIVE<xref rid="ehf212272-bib-0015" ref-type="ref">15</xref> trials were not confirmatory, and levosimendan is not licensed in the USA. Early enthusiasm led to rapid adoption in Europe, and although European guidelines do not give preference among different inotropes,<xref rid="ehf212272-bib-0002" ref-type="ref">2</xref> in the Swedish Heart Failure Registry, levosimendan is the overwhelming inotropic agent of choice by cardiologists.<xref rid="ehf212272-bib-0021" ref-type="ref">21</xref> Furthermore, the ease of administration and long half&#x02010;life allow administration to ambulatory patients in general cardiology wards or even as shortened infusions in office settings. Indeed, in Sweden between 2000 and 2011, the proportion of levosimendan treatments that were in stable patients ranged widely between 0% and 65% between different hospitals,<xref rid="ehf212272-bib-0021" ref-type="ref">21</xref> but it is unclear whether this practice is justified.</p><p>Several small observational and randomized studies were reviewed<xref rid="ehf212272-bib-0019" ref-type="ref">19</xref> and summarized<xref rid="ehf212272-bib-0030" ref-type="ref">30</xref> and recently updated<xref rid="ehf212272-bib-0022" ref-type="ref">22</xref> in meta&#x02010;analysis and suggested that in selected patients, repetitive or intermittent levosimendan appears promising and may improve outcomes including mortality but selection criteria may need improvement. However, in SURVIVE, levosimendan was associated with borderline better 31&#x000a0;day survival compared with dobutamine in the majority of patients with a history of HF prior to the relevant ADHF episode (hazard ratio 0.52&#x02013;1.03, <italic>P</italic> for interaction&#x000a0;=&#x000a0;0.05), consistent with a potential benefit in stable patients with chronic HF. We studied a single use of levosimendan in advanced but stable chronic HF, which is different from repetitive or intermittent use; however, the patient population is similar as both of them have stable chronic HF. Our findings of distinct improvements in haemodynamics and NT&#x02010;pro&#x02010;BNP are consistent with these studies and suggest that the benefits in chronic stable HF may be mediated similarly to that in ADHF and may be extended to include other stable patients irrespective of levosimendan use. However, in the largest trial to date, LevoRep,<xref rid="ehf212272-bib-0023" ref-type="ref">23</xref> 120 outpatients were randomized to 6&#x000a0;h of 0.2&#x000a0;&#x003bc;g/kg/min infusions of levosimendan or placebo at 2&#x000a0;week intervals over 6&#x000a0;weeks without effect on the 6&#x000a0;min walk test or Kansas City Cardiomyopathy Questionnaire. However, the 65&#x02010;patient LION&#x02010;HEART trial did show a reduction in NT&#x02010;pro&#x02010;BNP area under the curve and was also promising in secondary morbidity outcomes, but the rationale for, indications for, and effects of as needed or repetitive treatments with levosimendan require further study.</p><p>These conflicting data suggest that certain clinical phenotypes may benefit whereas others may not and that these cannot be distinguished by simple inclusion criteria such as EF, NYHA class, and symptoms (such as the 6&#x000a0;min walk test as in LevoRep). Similarly to other HF settings, we attempted to identify predictors of levosimendan response, so as to &#x0201c;enrich&#x0201d; and improve the design of future trials. However, our small study could not identify any single clinical or haemodynamic factor that predicts levosimendan efficacy. Further studies are warranted to determine predictors of haemodynamic response in this patient population.</p><sec id="ehf212272-sec-0012"><title>Limitations</title><p>Our study is limited by the small sample size, and our findings need confirmation in a larger study. The small sample size did not allow meaningful assessment of outcomes such as quality of life or reaching transplantation. We used PBF as a surrogate for CO, which due to shunts may entail limitations for cross&#x02010;sectional between&#x02010;patient comparisons but is reliable for within&#x02010;patient, changes over time, the primary measure in our study. Moreover, electrocardiography and echocardiographic examination were not performed in the current study; subsequently, they were not included in our discussion about the haemodynamic effect of a single&#x02010;dose levosimendan. Another limitation is that we did not use a control group with placebo infusion. Therefore, the results from this study may have been subjected to a placebo effect. The placebo effect may have affected the degree of the positive effect of a single&#x02010;dose levosimendan but cannot explain the whole effect. In uncontrolled settings, a placebo effect cannot be ruled out, but in prior randomized trials, placebo has not affected CO or stroke volume.<xref rid="ehf212272-bib-0028" ref-type="ref">28</xref>, <xref rid="ehf212272-bib-0032" ref-type="ref">32</xref>
</p></sec></sec><sec id="ehf212272-sec-0013"><title>Conclusions</title><p>In patients with advanced but stable HF with reduced EF, levosimendan was associated with improved haemodynamics. However, we could not identify predictors of levosimendan's haemodynamic effect.</p></sec><sec id="ehf212272-sec-0015"><title>Conflict of interest</title><p>L.&#x000a0;H.&#x000a0;L.: No disclosures directly related to the present work. Unrelated disclosures are as follows: Research grants from Astra Zeneca and Boston Scientific; consulting or speaker's honoraria from Novartis, Astra Zeneca, Bayer, St Jude, Medtronic, and Vifor Pharma.</p><p>Other authors: None.</p></sec><sec id="ehf212272-sec-0014"><title>Funding</title><p>OrionPharma Inc.; Swedish Research Council (2013&#x02010;23897&#x02010;104604&#x02010;23); Swedish Heart Lung Foundation (20150063); Stockholm County Council (20090556, 20110120).</p></sec></body><back><ref-list id="ehf212272-bibl-0001" content-type="cited-references"><title>References</title><ref id="ehf212272-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ehf212272-cit-0002">
<string-name>
<surname>Lund</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Mancini</surname>
<given-names>D</given-names>
</string-name>. <article-title>Heart failure in women</article-title>. <source>Med Clin North Am</source>
<year>2004</year>; <volume>88</volume>: <fpage>1321</fpage>&#x02013;<lpage>1345</lpage> xii.<pub-id pub-id-type="pmid">15331319</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ehf212272-cit-0003">
<string-name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Adamopoulos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Auricchio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bohm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dickstein</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Falk</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Filippatos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gomez&#x02010;Sanchez</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Jaarsma</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kober</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lip</surname>
<given-names>GY</given-names>
</string-name>, <string-name>
<surname>Maggioni</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Parkhomenko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pieske</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Popescu</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Ronnevik</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Rutten</surname>
<given-names>FH</given-names>
</string-name>, <string-name>
<surname>Schwitter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Seferovic</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Stepinska</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Trindade</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Voors</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Zannad</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zeiher</surname>
<given-names>A</given-names>
</string-name>. <article-title>ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC</article-title>. <source>Eur Heart J</source>
<year>2012</year>; <volume>33</volume>: <fpage>1787</fpage>&#x02013;<lpage>1847</lpage>.<pub-id pub-id-type="pmid">22611136</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ehf212272-cit-0004">
<string-name>
<surname>Jessup</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brozena</surname>
<given-names>S</given-names>
</string-name>. <article-title>Heart failure</article-title>. <source>N Engl J Med</source>
<year>2003</year>; <volume>348</volume>: <fpage>2007</fpage>&#x02013;<lpage>2018</lpage>.<pub-id pub-id-type="pmid">12748317</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ehf212272-cit-0005">
<string-name>
<surname>Nieminen</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Brutsaert</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dickstein</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Drexler</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Follath</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Harjola</surname>
<given-names>VP</given-names>
</string-name>, <string-name>
<surname>Hochadel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Komajda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lassus</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lopez&#x02010;Sendon</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Ponikowski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tavazzi</surname>
<given-names>L</given-names>
</string-name>; 
<collab collab-type="authors">EuroHeart Survey Investigators</collab>
; 
<collab collab-type="authors">Heart Failure Association, European Society of Cardiology</collab>
. <article-title>EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population</article-title>. <source>Eur Heart J</source>
<year>2006</year>; <volume>27</volume>: <fpage>2725</fpage>&#x02013;<lpage>2736</lpage>.<pub-id pub-id-type="pmid">17000631</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ehf212272-cit-0006">
<string-name>
<surname>Cuffe</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>KF</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Benza</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bourge</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Colucci</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Massie</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>O'Connor</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Pina</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Quigg</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Silver</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Gheorghiade</surname>
<given-names>M</given-names>
</string-name>; 
<collab collab-type="authors">Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME&#x02010;CHF) Investigators</collab>
. <article-title>Short&#x02010;term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial</article-title>. <source>JAMA</source>
<year>2002</year>; <volume>287</volume>: <fpage>1541</fpage>&#x02013;<lpage>1547</lpage>.<pub-id pub-id-type="pmid">11911756</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ehf212272-cit-0007">
<string-name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Fonarow</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Costanzo</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Berkowitz</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>LeJemtel</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Wynne</surname>
<given-names>J</given-names>
</string-name>; 
<collab collab-type="authors">ADHERE Scientific Advisory Committee and Investigators</collab>
; 
<collab collab-type="authors">ADHERE Study Group</collab>
. <article-title>In&#x02010;hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)</article-title>. <source>J Am Coll Cardiol</source>
<year>2005</year>; <volume>46</volume>: <fpage>57</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">15992636</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ehf212272-cit-0008">
<string-name>
<surname>Remondino</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kwon</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Communal</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pimentel</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Sawyer</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Colucci</surname>
<given-names>WS</given-names>
</string-name>. <article-title>Beta&#x02010;adrenergic receptor&#x02010;stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c&#x02010;Jun NH2&#x02010;terminal kinase&#x02010;dependent activation of the mitochondrial pathway</article-title>. <source>Circ Res</source>
<year>2003</year>; <volume>92</volume>: <fpage>136</fpage>&#x02013;<lpage>138</lpage>.<pub-id pub-id-type="pmid">12574140</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ehf212272-cit-0009">
<string-name>
<surname>Tacon</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>McCaffrey</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Delaney</surname>
<given-names>A</given-names>
</string-name>. <article-title>Dobutamine for patients with severe heart failure: a systematic review and meta&#x02010;analysis of randomised controlled trials</article-title>. <source>Intensive Care Med</source>
<year>2012</year>; <volume>38</volume>: <fpage>359</fpage>&#x02013;<lpage>367</lpage>.<pub-id pub-id-type="pmid">22160239</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ehf212272-cit-0010">
<string-name>
<surname>Nony</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Boissel</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Lievre</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leizorovicz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Haugh</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Fareh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>de Breyne</surname>
<given-names>B</given-names>
</string-name>. <article-title>Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta&#x02010;analysis</article-title>. <source>Eur J Clin Pharmacol</source>
<year>1994</year>; <volume>46</volume>: <fpage>191</fpage>&#x02013;<lpage>196</lpage>.<pub-id pub-id-type="pmid">8070498</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ehf212272-cit-0011">
<string-name>
<surname>McBride</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>CM</given-names>
</string-name>. <article-title>Levosimendan: implications for clinicians</article-title>. <source>J Clin Pharmacol</source>
<year>2003</year>; <volume>43</volume>: <fpage>1071</fpage>&#x02013;<lpage>1081</lpage>.<pub-id pub-id-type="pmid">14517189</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ehf212272-cit-0012">
<string-name>
<surname>Toller</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Algotsson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Guarracino</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hormann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Knotzer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lehmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rajek</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Salmenper&#x000e4;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schirmer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Tritapepe</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Weis</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Landoni</surname>
<given-names>G</given-names>
</string-name>. <article-title>Perioperative use of levosimendan: best practice in operative settings</article-title>. <source>J Cardiothorac Vasc Anesth</source>
<year>2013</year>; <volume>27</volume>: <fpage>361</fpage>&#x02013;<lpage>366</lpage>.<pub-id pub-id-type="pmid">22658687</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ehf212272-cit-0013">
<string-name>
<surname>Follath</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cleland</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Just</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Papp</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Scholz</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Peuhkurinen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Harjola</surname>
<given-names>VP</given-names>
</string-name>, <string-name>
<surname>Mitrovic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Abdalla</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sandell</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Lehtonen</surname>
<given-names>L</given-names>
</string-name>; 
<collab collab-type="authors">Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study</collab>
. <article-title>Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low&#x02010;output heart failure (the LIDO study): a randomised double&#x02010;blind trial</article-title>. <source>Lancet</source>
<year>2002</year>; <volume>360</volume>: <fpage>196</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">12133653</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ehf212272-cit-0014">
<string-name>
<surname>Moiseyev</surname>
<given-names>VS</given-names>
</string-name>, <string-name>
<surname>Poder</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Andrejevs</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ruda</surname>
<given-names>MY</given-names>
</string-name>, <string-name>
<surname>Golikov</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Lazebnik</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Kobalava</surname>
<given-names>ZD</given-names>
</string-name>, <string-name>
<surname>Lehtonen</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Laine</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nieminen</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Lie</surname>
<given-names>KI</given-names>
</string-name>; 
<collab collab-type="authors">RUSSLAN Study Investigators</collab>
. <article-title>Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo&#x02010;controlled, double&#x02010;blind study (RUSSLAN)</article-title>. <source>Eur Heart J</source>
<year>2002</year>; <volume>23</volume>: <fpage>1422</fpage>&#x02013;<lpage>1432</lpage>.<pub-id pub-id-type="pmid">12208222</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ehf212272-cit-0015">
<string-name>
<surname>Mebazaa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nieminen</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Filippatos</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Cleland</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Salon</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Thakkar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Padley</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cohen&#x02010;Solal</surname>
<given-names>A</given-names>
</string-name>. <article-title>Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta&#x02010;blockers in SURVIVE</article-title>. <source>Eur J Heart Fail</source>
<year>2009</year>; <volume>11</volume>: <fpage>304</fpage>&#x02013;<lpage>311</lpage>.<pub-id pub-id-type="pmid">19158152</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ehf212272-cit-0016">
<string-name>
<surname>Packer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Colucci</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Massie</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Teerlink</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Padley</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Thakkar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Delgado&#x02010;Herrera</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Salon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Garratt</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Sarapohja</surname>
<given-names>T</given-names>
</string-name>; 
<collab collab-type="authors">REVIVE Heart Failure Study Group</collab>
. <article-title>Effect of levosimendan on the short&#x02010;term clinical course of patients with acutely decompensated heart failure</article-title>. <source>JACC Heart Fail</source>
<year>2013</year>; <volume>1</volume>: <fpage>103</fpage>&#x02013;<lpage>111</lpage>.<pub-id pub-id-type="pmid">24621834</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ehf212272-cit-0017">
<string-name>
<surname>Miller</surname>
<given-names>LW</given-names>
</string-name>. <article-title>Left ventricular assist devices are underutilized</article-title>. <source>Circulation</source>
<year>2011</year>; <volume>123</volume>: <fpage>1552</fpage>&#x02013;<lpage>1558</lpage> discussion 8.<pub-id pub-id-type="pmid">21482973</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ehf212272-cit-0018">
<string-name>
<surname>O'Connor</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Gattis</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Uretsky</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>KF</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>McNulty</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Grossman</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>McKenna</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Zannad</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Swedberg</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gheorghiade</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Califf</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)</article-title>. <source>Am Heart J</source>
<year>1999</year>; <volume>138</volume>: <fpage>78</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">10385768</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ehf212272-cit-0019">
<string-name>
<surname>Rapezzi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bracchetti</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Branzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Magnani</surname>
<given-names>B</given-names>
</string-name>. <article-title>The case against outpatient parenteral inotropic therapy for advanced heart failure</article-title>. <source>J Heart Lung Transplant</source>
<year>2000</year>; <volume>19</volume>: <fpage>S58</fpage>&#x02013;<lpage>S63</lpage>.</mixed-citation></ref><ref id="ehf212272-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ehf212272-cit-0020">
<string-name>
<surname>Nieminen</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Altenberger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ben&#x02010;Gal</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bohmer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Comin&#x02010;Colet</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dickstein</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Edes</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Fedele</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Garc&#x000ed;a&#x02010;Gonz&#x000e1;lez</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Giannakoulas</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Iakobishvili</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>J&#x000e4;&#x000e4;skel&#x000e4;inen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Karavidas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kettner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kivikko</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lund</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Matskeplishvili</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Metra</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morandi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Oliva</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Parkhomenko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Parissis</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pollesello</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>P&#x000f6;lzl</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schwinger</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Segovia</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Seidel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vrtovec</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wikstr&#x000f6;m</surname>
<given-names>G</given-names>
</string-name>. <article-title>Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus</article-title>. <source>Int J Cardiol</source>
<year>2014</year>; <volume>174</volume>: <fpage>360</fpage>&#x02013;<lpage>367</lpage>.<pub-id pub-id-type="pmid">24780540</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ehf212272-cit-0021">
<string-name>
<surname>Lilleberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Laine</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Palkama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kivikko</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pohjanjousi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kupari</surname>
<given-names>M</given-names>
</string-name>. <article-title>Duration of the haemodynamic action of a 24&#x02010;h infusion of levosimendan in patients with congestive heart failure</article-title>. <source>Eur J Heart Fail</source>
<year>2007</year>; <volume>9</volume>: <fpage>75</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">16829185</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ehf212272-cit-0022">
<string-name>
<surname>Thorvaldsen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Benson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hagerman</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Dahlstrom</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Edner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lund</surname>
<given-names>LH</given-names>
</string-name>. <article-title>Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden</article-title>. <source>Int J Cardiol</source>
<year>2014</year>; <volume>175</volume>: <fpage>55</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">24820737</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ehf212272-cit-0023">
<string-name>
<surname>Silvetti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nieminen</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta&#x02010;analysis</article-title>. <source>Int J Cardiol</source>
<year>2016</year>; <volume>202</volume>: <fpage>138</fpage>&#x02013;<lpage>143</lpage>.<pub-id pub-id-type="pmid">26386941</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ehf212272-cit-0024">
<string-name>
<surname>Altenberger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parissis</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Costard&#x02010;Jaeckle</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Winter</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ebner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Karavidas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sihorsch</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Avgeropoulou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Weber</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dimopoulos</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ulmer</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Poelzl</surname>
<given-names>G</given-names>
</string-name>. <article-title>Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial</article-title>. <source>Eur J Heart Fail</source>
<year>2014</year>; <volume>16</volume>: <fpage>898</fpage>&#x02013;<lpage>906</lpage>.<pub-id pub-id-type="pmid">24920349</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ehf212272-cit-0025">
<string-name>
<surname>Pellicori</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>AL</given-names>
</string-name>. <article-title>Clinical trials update from the European Society of Cardiology&#x02010;Heart Failure meeting 2015: AUGMENT&#x02010;HF, TITRATION, STOP&#x02010;HF, HARMONIZE, LION HEART, MOOD&#x02010;HF, and renin&#x02013;angiotensin inhibitors in patients with heart and renal failure</article-title>. <source>Eur J Heart Fail</source>
<year>2015</year>; <volume>17</volume>: <fpage>979</fpage>&#x02013;<lpage>983</lpage>.<pub-id pub-id-type="pmid">26289928</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ehf212272-cit-0026">
<string-name>
<surname>Gabrielsen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Videbaek</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Damgaard</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kastrup</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Norsk</surname>
<given-names>P</given-names>
</string-name>. <article-title>Non&#x02010;invasive measurement of cardiac output in heart failure patients using a new foreign gas rebreathing technique</article-title>. <source>Clin Sci (Lond)</source>
<year>2002</year>; <volume>102</volume>: <fpage>247</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">11834145</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ehf212272-cit-0027">
<string-name>
<surname>Levey</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>Castro</surname>
<given-names>AF</given-names>
<suffix>3rd</suffix>
</string-name>, <string-name>
<surname>Feldman</surname>
<given-names>HI</given-names>
</string-name>, <string-name>
<surname>Kusek</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Eggers</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Van Lente</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Greene</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Coresh</surname>
<given-names>J</given-names>
</string-name>; 
<collab collab-type="authors">CKD&#x02010;EPI (Chronic Kidney Disease Epidemiology Collaboration)</collab>
. <article-title>A new equation to estimate glomerular filtration rate</article-title>. <source>Ann Intern Med</source>
<year>2009</year>; <volume>150</volume>: <fpage>604</fpage>&#x02013;<lpage>612</lpage>.<pub-id pub-id-type="pmid">19414839</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ehf212272-cit-0028">
<string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>CY</given-names>
</string-name>. <article-title>Validation of the use of foreign gas rebreathing method for non&#x02010;invasive determination of cardiac output in heart disease patients</article-title>. <source>J Zhejiang Univ Sci B</source>
<year>2005</year>; <volume>6</volume>: <fpage>1157</fpage>&#x02013;<lpage>1162</lpage>.<pub-id pub-id-type="pmid">16358372</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ehf212272-cit-0029">
<string-name>
<surname>Slawsky</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Colucci</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Gottlieb</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Greenberg</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Haeusslein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hare</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hutchins</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Leier</surname>
<given-names>CV</given-names>
</string-name>, <string-name>
<surname>LeJemtel</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Loh</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nicklas</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ogilby</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>W</given-names>
</string-name>. <article-title>Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators</article-title>. <source>Circulation</source>
<year>2000</year>; <volume>102</volume>: <fpage>2222</fpage>&#x02013;<lpage>2227</lpage>.<pub-id pub-id-type="pmid">11056096</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ehf212272-cit-0030">
<string-name>
<surname>Parissis</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Panou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Farmakis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Adamopoulos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Filippatos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Paraskevaidis</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Venetsanou</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lekakis</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kremastinos</surname>
<given-names>DT</given-names>
</string-name>. <article-title>Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure</article-title>. <source>Am J Cardiol</source>
<year>2005</year>; <volume>96</volume>: <fpage>423</fpage>&#x02013;<lpage>426</lpage>.<pub-id pub-id-type="pmid">16054474</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ehf212272-cit-0031">
<string-name>
<surname>Silvetti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Greco</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Di Prima</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Mucchetti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>de Lurdes</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Pasin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Scandroglio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Landoni</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zangrillo</surname>
<given-names>A</given-names>
</string-name>. <article-title>Intermittent levosimendan improves mid&#x02010;term survival in chronic heart failure patients: meta&#x02010;analysis of randomised trials</article-title>. <source>Clin Res Cardiol</source>
<year>2014</year>; <volume>103</volume>: <fpage>505</fpage>&#x02013;<lpage>513</lpage>.<pub-id pub-id-type="pmid">24368740</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ehf212272-cit-0032">
<string-name>
<surname>Moreno</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tavares&#x02010;Silva</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lourenco</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Oliveira&#x02010;Pinto</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Henriques&#x02010;Coelho</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Leite&#x02010;Moreira</surname>
<given-names>AF</given-names>
</string-name>. <article-title>Levosimendan: the current situation and new prospects</article-title>. <source>Rev Port Cardiol</source>
<year>2014</year>; <volume>33</volume>: <fpage>795</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">25459636</pub-id></mixed-citation></ref><ref id="ehf212272-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ehf212272-cit-0033">
<string-name>
<surname>Jorgensen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bech&#x02010;Hanssen</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Houltz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ricksten</surname>
<given-names>SE</given-names>
</string-name>. <article-title>Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis</article-title>. <source>Circulation</source>
<year>2008</year>; <volume>117</volume>: <fpage>1075</fpage>&#x02013;<lpage>1081</lpage>.<pub-id pub-id-type="pmid">18268152</pub-id></mixed-citation></ref></ref-list></back></article>